Jpmorgan Chase & CO Atossa Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Atossa Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 53,999 shares of ATOS stock, worth $82,078. This represents 0.0% of its overall portfolio holdings.
Number of Shares
53,999
Previous 94
57345.74%
Holding current value
$82,078
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding ATOS
# of Institutions
81Shares Held
25.8MCall Options Held
404KPut Options Held
83.6K-
Black Rock Inc. New York, NY9.2MShares$14 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.49MShares$9.86 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.77MShares$4.21 Million0.0% of portfolio
-
State Street Corp Boston, MA1.66MShares$2.53 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.55MShares$2.36 Million0.0% of portfolio
About ATOSSA THERAPEUTICS, INC.
- Ticker ATOS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 126,624,000
- Market Cap $192M
- Description
- Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing A...